Indaptus Therapeutics is trading 5% higher at $1.36 in a technical rebound following several days of sharp declines and profit-taking.
- The move comes despite a lack of fresh company-specific headlines, regulatory updates, or analyst actions this morning.
- The recovery appears to be driven by a broadly positive U.S. equity backdrop as the stock stabilizes following a pullback from its prior rally.